Scleroderma
June 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Scleroderma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Scleroderma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Scleroderma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Scleroderma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature.
Authors:Sanges S, Riviere S, Mekinian A, Martin T, Le Quellec A, Chatelus E, Lescoat A, Jego P, Cazalets C, Quemeneur T, Le Gouellec N, Senet P, Frances C, Deroux A, Imbert B, Fain O, Boukari L, Sene T, Deligny C, Mathian A, Agard C, Pugnet G, Speca S, Dubucquoi S, Hatron PY, Hachulla E, Launay D
Institution:Univ. Lille, INSERM U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France; INSERM, U995, F-59000 Lille, France; CHU Lille, Departement de Medecine Interne et Immunologie Clinique, F-59000 Lille, France; Centre National de Reference Maladies Systemiques et Auto-immunes Rares (Sclerodermie Systemique), F-59000 Lille, France; Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET). Universite Paris 06, Faculte de Medecine Pierre et Marie Curie, Paris, France. Universite Paris 06, Faculte de Medecine Pierre et Marie Curie, Paris, France. 3572, Strasbourg, France. Saint-Eloi, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, France. Centre de Reference des Maladies Auto-Immunes Systemiques Rares, Universite de Strasbourg, Federation de Medecine Translationnelle de Strasbourg, INSERM UMR 1109, Strasbourg, France. de Rennes 1, Rennes, France. de Rennes 1, Rennes, France. de Rennes 1, Rennes, France. Hospitalier de Valenciennes, Valenciennes, France. Hospitalier de Valenciennes, Valenciennes, France. Universitaire (CHU) de Grenoble, Grenoble, France. Universitaire (CHU) de Grenoble, Grenoble, France. Universite Paris 06, Faculte de Medecine Pierre et Marie Curie, Paris, France. Bondy, France. Paris, France. Universitaire Pierre Zobda-Quitman, Fort-de-France, Martinique. Syndrome des Antiphospholipides, institut E3M, Groupe Hospitalier Pitie-Salpetriere, AP-HP, Paris, France; Sorbonne universites, UPMC universite Paris 06, 75013 Paris, France. Nantes, France. Toulouse, France; INSERM, UMR 1027, Toulouse, France. Center, F-59000 Lille, France; INSERM, U995, F-59000 Lille, France. Center, F-59000 Lille, France; INSERM, U995, F-59000 Lille, France. Center, F-59000 Lille, France; CHU Lille, Departement de Medecine Interne et Immunologie Clinique, F-59000 Lille, France; Centre National de Reference Maladies Systemiques et Auto-immunes Rares (Sclerodermie Systemique), F-59000 Lille, France; Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET). Center, F-59000 Lille, France; INSERM, U995, F-59000 Lille, France; CHU Lille, Departement de Medecine Interne et Immunologie Clinique, F-59000 Lille, France; Centre National de Reference Maladies Systemiques et Auto-immunes Rares (Sclerodermie Systemique), F-59000 Lille, France; Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET). Center, F-59000 Lille, France; INSERM, U995, F-59000 Lille, France; CHU Lille, Departement de Medecine Interne et Immunologie Clinique, F-59000 Lille, France; Centre National de Reference Maladies Systemiques et Auto-immunes Rares (Sclerodermie Systemique), F-59000 Lille, France; Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET). Electronic address: david.launay@univ-lille2.fr.
Journal:Autoimmun Rev. 2017 Apr;16(4):377-384. doi: 10.1016/j.autrev.2017.02.008. Epub 2017 Feb 13.

2:Systemic sclerosis and exposure to heavy metals: A case control study of 100 patients and 300 controls.
Authors:Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, Bravard P, Noel D, Cailleux AF, Benichou J, Levesque H, Goulle JP
Institution:Department of Internal Medicine, CHU Rouen, and INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, F-76000 Rouen, France. Electronic address: isabelle.marie@chu-rouen.fr. Research, CHU Rouen, Rouen, France. IFRMP, Institute for Biochemical Research, F-76000 Rouen, France.
Journal:Autoimmun Rev. 2017 Mar;16(3):223-230. doi: 10.1016/j.autrev.2017.01.004. Epub 2017 Jan 27.

3:Occupational and environmental scleroderma. Systematic review and meta-analysis.
Authors:Rubio-Rivas M, Moreno R, Corbella X
Institution:Autoimmune Diseases Unit. Department of Internal Medicine, Bellvitge University Hospital-IDIBELL. L'Hospitalet de Llobregat, Feixa Llarga s/n, Hospitalet de Llobregat, Barcelona, Spain. mrubio@bellvitgehospital.cat. Hospital-IDIBELL. L'Hospitalet de Llobregat, Feixa Llarga s/n, Hospitalet de Llobregat, Barcelona, Spain. Hospital-IDIBELL. L'Hospitalet de Llobregat, Feixa Llarga s/n, Hospitalet de Llobregat, Barcelona, Spain. Barcelona, Spain.
Journal:Clin Rheumatol. 2017 Mar;36(3):569-582. doi: 10.1007/s10067-016-3533-1. Epub 2017 Jan 14.

4:Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Authors:Michelfelder M, Becker M, Riedlinger A, Siegert E, Dromann D, Yu X, Petersen F, Riemekasten G
Institution:Department of Anesthesiology, University Hospital Bonn, Bonn, Germany. gabriela.riemekasten@uksh.de. gabriela.riemekasten@uksh.de. gabriela.riemekasten@uksh.de.
Journal:Clin Rheumatol. 2017 Feb;36(2):381-390. doi: 10.1007/s10067-016-3504-6. Epub 2016 Dec 27.

5:Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
Authors:Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Clements PJ, Theodore A, Kafaja S, Kim GH, Goldin J, Ariolla E, Elashoff RM
Institution:Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address: dtashkin@mednet.ucla.edu. Angeles, CA. Angeles, CA. Los Angeles, CA. Angeles, CA.
Journal:Chest. 2017 Apr;151(4):813-820. doi: 10.1016/j.chest.2016.11.052. Epub 2016 Dec 22.

6:Genomic and genetic studies of systemic sclerosis: A systematic review.
Authors:Chairta P, Nicolaou P, Christodoulou K
Institution:Neurogenetics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus; Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus. 2370, Cyprus; Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus. 2370, Cyprus; Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus. Electronic address: roula@cing.ac.cy.
Journal:Hum Immunol. 2017 Feb;78(2):153-165. doi: 10.1016/j.humimm.2016.10.017. Epub 2016 Oct 29.

7:Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
Authors:Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP
Institution:Universite Paris-Sud, Faculte de Medecine, Universite Paris-Saclay, Le Kremlin Bicetre, France. Lung Research (DZL)), Giessen, Germany. Lung Research (DZL)), Giessen, Germany. China.
Journal:Ann Rheum Dis. 2017 Feb;76(2):422-426. doi: 10.1136/annrheumdis-2015-209087. Epub 2016 Jul 25.

8:Physical capacity in performing daily activities is reduced in scleroderma patients with early lung involvement.
Authors:Battaglia S, Bellia M, Serafino-Agrusa L, Giardina A, Messina M, Cannizzaro F, Midiri M, Triolo G, Scichilone N
Institution:Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.MIS), Sezione di Pneumologia, University of Palermo, Palermo, Italy. di Pneumologia, University of Palermo, Palermo, Italy. di Pneumologia, University of Palermo, Palermo, Italy. di Reumatologia, University of Palermo, Palermo, Italy. di Pneumologia, University of Palermo, Palermo, Italy. di Scienze Radiologiche, University of Palermo, Palermo, Italy. di Scienze Radiologiche, University of Palermo, Palermo, Italy. di Reumatologia, University of Palermo, Palermo, Italy. di Pneumologia, University of Palermo, Palermo, Italy.
Journal:Clin Respir J. 2017 Jan;11(1):36-42. doi: 10.1111/crj.12299. Epub 2015 May 6.

For a FREE PREVIEW of the Medifocus Guidebook on Scleroderma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Scleroderma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Scleroderma...
at a Special 20% Discount


Medifocus Guidebook on Scleroderma

Updated: January 30, 2017
145 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Scleroderma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

SC12489100

Coupon Expires: July 22, 2017



What Our Customers Are Saying...

"I found the MediFocus Guidebook on Scleroderma to be very comprehensive and easy to read. While it covers the "basics" of the disease that all patients need to know, it also provides more advanced information about the latest research and scientific advances. In a nutshell, the Scleroderma Guidebook is a tremendous resource for anyone who wants to become more educated about this autoimmune disorder and gain a clearer understanding of the medical issues."
L.M.R.
Danville, Virginia


"The MediFocus Guidebook on Scleroderma provides a vast amount of important, practical information about this condition that is supported by an extensive list of references from reputable medical sources. The Guidebook not only has helped to answer many of my questions but has also given me the confidence to discuss my treatment options with my Rheumatologist in far greater detail than I could have done before reading the book. Thank you for providing this valuable Guidebook."
G.D.
South Bend, Indiana


"The MediFocus Guidebook on Scleroderma helped me to understand my condition. In South Africa there is no support network for Scleroderma so your updates on new treatments will benefit me in educating myself to manage my disease. Thank you."
G.M.B.
Eastern Cape, South Africa



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.